Physician profile
Eric Weinstock
NPI 1679554687
$23,704.46
in general payments reported to CMS, 2019-2025
36 companies · $5,086 in 2025
The $5,086 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,708 · 2020: $1,981 · 2021: $2,193 · 2022: $2,923 · 2023: $6,311 · 2024: $3,503 · 2025: $5,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $1,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,423.51 |
| Consulting Fee | $1,476.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,711.14 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $2,173.58 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Abbvie INC. | $1,788.75 | 2021-2025 | Vraylar |
| Biogen, INC. | $1,476.00 | 2023 | |
| Harmony Biosciences LLC | $1,423.01 | 2020-2025 | |
| Alkermes, INC. | $1,411.51 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $1,196.99 | 2022-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $1,015.82 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Corium, LLC | $947.96 | 2021-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $946.17 | 2021-2025 | Ingrezza |
| Neos Therapeutics, Lp | $870.96 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Janssen Pharmaceuticals, INC | $753.62 | 2021-2025 | Spravato, Invega Sustenna, Invega |
| Noven Therapeutics, LLC | $738.83 | 2020-2025 | Xelstrym, Secuado |
| Lundbeck LLC | $693.03 | 2019-2025 | Rexulti |
| Almatica Pharma LLC | $686.09 | 2022-2025 | Loreev Xr, Gralise |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $611.64 | 2019-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $517.50 | 2019-2025 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $469.31 | 2022-2024 | Quviviq |
| Allergan, INC. | $414.67 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $384.99 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $354.23 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $326.47 | 2019-2025 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $280.68 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $276.87 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $251.33 | 2022-2025 | Qelbree |
| Eisai INC. | $248.24 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $208.95 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $131.45 | 2019-2021 | |
| Adlon Therapeutics L.P. | $124.49 | 2019-2021 | |
| Shire North American Group INC | $81.25 | 2019 | |
| Merck Sharp & Dohme LLC | $57.29 | 2020-2022 | |
| Aytu Biopharma, INC. | $37.57 | 2021 | |
| Arbor Pharmaceuticals, INC. | $30.35 | 2019-2020 | |
| Brainsway USA INC | $22.56 | 2024 | Brainsway Deep Tms System |
| Livanova USA, INC. | $22.12 | 2021 | |
| Collegium Pharmaceutical, INC. | $19.04 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Weinstock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.